


# PRODUCT INFORMATION



## Repaglinide

Item No. 19387

**CAS Registry No.:** 135062-02-1  
**Formal Name:** 2-ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-benzoic acid  
**MF:** C<sub>27</sub>H<sub>36</sub>N<sub>2</sub>O<sub>4</sub>  
**FW:** 452.6  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 243, 293 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Repaglinide is supplied as a crystalline solid. A stock solution may be made by dissolving the repaglinide in the solvent of choice, which should be purged with an inert gas. Repaglinide is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of repaglinide in ethanol is approximately 25 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Repaglinide is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, repaglinide should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Repaglinide has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Repaglinide is a metaglitinide antidiabetic agent that blocks ATP-dependent potassium (K<sub>ir</sub>6) channels in pancreatic β-cells (K<sub>d</sub> = 0.42 nM for the sulphonylurea receptor SUR1 when co-expressed with K<sub>ir</sub>6.2).<sup>1</sup> *In vivo*, repaglinide lowers blood glucose in fasted rats and dogs (ED<sub>50</sub>s = 10 and 28.3 μg/kg, respectively).<sup>2</sup> Formulations containing repaglinide have been used to control blood sugar levels in patients with type 2 diabetes.

### References

1. Hansen, A. M. K., Hansen, J. B., Carr, R. D., *et al.* K<sub>ir</sub>6.2-dependent high-affinity repaglinide binding to β-cell KATP channels. *Br. J. Pharmacol.* **144**(4), 551-557 (2005).
2. Mark, M. and Grell, W. Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs. *Br. J. Pharmacol.* **121**(8), 1597-1604 (1997).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/28/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM